FTY720 (fingolimod) for relapsing multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 8, Issue 5, 2008, Pages 699-714

  Horga, Alejandro ^a   Montalban, Xavier ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Fingolimod; FTY720; Multiple sclerosis; Sphingosine; Sphingosine 1 phosphate receptor

Indexed keywords

FINGOLIMOD; PLACEBO; SPHINGOSINE; SPHINGOSINE 1 PHOSPHATE;

ALLERGIC ENCEPHALOMYELITIS; AREA UNDER THE CURVE; BIOTRANSFORMATION; BRAIN DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FORCED EXPIRATORY VOLUME; GLIA CELL; HEADACHE; HUMAN; IMMUNOMODULATION; LUNG FUNCTION TEST; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MULTIPLE SCLEROSIS; NAUSEA; NEUROIMAGING; NONHUMAN; RECURRENT DISEASE; REVIEW; RHINOPHARYNGITIS; RISK BENEFIT ANALYSIS; STEM CELL; STRUCTURE ACTIVITY RELATION; TISSUE REPAIR;

CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; RECURRENCE; SPHINGOSINE; TREATMENT OUTCOME;

EID: 43249119649     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.8.5.699     Document Type: Review

References (150)

1. Pugliatti M, Rosati G, Carton H et al. The epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 13(7), 700-722 (2006).
2. Compston A, Coles A. Multiple sclerosis. Lancet 359(9313), 1221-1231 (2002).
3. Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2), 169-178 (2002).
4. Ransohoff RM. Natalizumab for multiple sclerosis. N. Engl. J. Med. 356(25), 2622-2629 (2007).
5. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs 19(3), 239-252 (2005).
6. Fujita T, Inoue K, Yamamoto S et al. Fungal metabolites. Part 11. A potent immunosuppressive activity found in Isaria sinclairii metabolite. J. Antibiot. (Tokyo) 47(2), 208-215 (1994).
7. Adachi K, Kohara T, Nakao N et al. Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediols: discovery of a novel immunosuppressant, FTY720. Bioorg. Med. Chem. Lett. 5(8), 853-856 (1995). • First description a novel synthetic drug, FTY720, as a very potent myriocin-like compound.
8. Martini S, Peters H, Bohler T, Budde K. Current perspectives on FTY720. Expert Opin. Investig. Drugs 16(4), 505-518 (2007).
9. Budde K, Schutz M, Glander P et al. FTY720 (fingolimod) in renal transplantation. Clin. Transplant. 20(Suppl. 17), 17-24 (2006).
10. Salvadori M, Budde K, Charpentier B et al. FTY720 versus MMF with cyclosporine in de novo renal transplantation: a 1-year, randomized controlled trial in Europe and Australasia. Am. J. Transplant. 6(12), 2912-2921 (2006). • One of the two Phase III pivotal clinical trials showing efficacy and safety results in de novo renal transplant patients.
11. Tedesco-Silva H, Pescovitz MD, Cibrik D et al. Randomized controlled trial of FTY720 versus MMF in de novo renal transplantation. Transplantation 82(12), 1689-1697 (2006). • One of the two Phase III pivotal clinical trials showing efficacy and safety results in de novo renal transplant patients.
12. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 355(11), 1124-1140 (2006). •• First Phase II clinical trial showing the efficacy of oral monotherapy with FTY720 in relapsing multiple sclerosis.
13. Mandala S, Hajdu R, Bergstrom J et al. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science 296(5566), 346-349 (2002). •• One of two first demonstrations that FTY720 targets sphingosine-1-phosphate (S1P) receptors.
14. Brinkmann V, Davis MD, Heise CE et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J. Biol. Chem. 277(24), 21453-21457 (2002). •• One of two first demonstrations that FTY720 targets S1P receptors and the first study showing the efficacy of FTY720 in an experimental autoimmune encephalomyelitis model.
15. Albert R, Hinterding K, Brinkmann V et al. Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer. J. Med. Chem. 48(16), 5373-5377 (2005).
16. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 115(1), 84-105 (2007).
17. Spiegel S, Cuvillier O, Edsall LC et al. Sphingosine-1-phosphate in cell growth and cell death. Ann. NY Acad. Sci. 845, 11-18 (1998).
18. Spiegel S, Milstien S. Sphingolipid metabolites: members of a new class of lipid second messengers. J. Membr. Biol. 146(3), 225-237 (1995).
19. Hla T. Signaling and biological actions of sphingosine 1-phosphate. Pharmacol. Res. 47(5), 401-407 (2003).
20. Lee MJ, Van Brocklyn JR, Thangada S et al. Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. Science. 279(5356), 1552-1555 (1998).
21. Lee JF, Zeng Q, Ozaki H et al. Dual roles of tight junction-associated protein, zonula occludens-1, in sphingosine 1-phosphate-mediated endothelial chemotaxis and barrier integrity. J. Biol. Chem. 281(39), 29190-29200 (2006).
22. Allende ML, Yamashita T, Proia RL. G-protein-coupled receptor S1P1 acts within endothelial cells to regulate vascular maturation. Blood 102(10), 3665-3667 (2003).
23. Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell. Biol. 25(24), 11113-11121 (2005).
24. Saba JD. Lysophospholipids in development: miles apart and edging in. J. Cell. Biochem. 92(5), 967-992 (2004).
25. Hannun YA, Luberto C, Argraves KM. Enzymes of sphingolipid metabolism: from modular to integrative signaling. Biochemistry 40(16), 4893-4903 (2001).
26. Le Stunff H, Milstien S, Spiegel S. Generation and metabolism of bioactive sphingosine-1-phosphate. J. Cell. Biochem. 92(5), 882-899 (2004).
27. Murata N, Sato K, Kon J et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J. 352(Pt 3), 809-815 (2000).
28. Sanchez T, Hla T. Structural and functional characteristics of S1P receptors. J. Cell. Biochem. 92(5), 913-922 (2004).
29. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5(7), 560-570 (2005).
30. Hu W, Mahavadi S, Huang J, Li F, Murthy KS. Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection. Am. J. Physiol. Gastrointest. Liver. Physiol. 291(4), G605-G610 (2006).
31. Graler MH, Grosse R, Kusch A, Kremmer E, Gudermann T, Lipp M. The sphingosine 1-phosphate receptor S1P4 regulates cell shape and motility via coupling to Gi and G12/13. J. Cell. Biochem. 89(3), 507-519 (2003).
32. Rosen H, Sanna G, Alfonso C. Egress: a receptor-regulated step in lymphocyte trafficking. Immunol. Rev. 195, 160-177 (2003).
33. Lo CG, Xu Y, Proia RL, Cyster JG. Cyclical modulation of sphingosine-1-phosphate receptor 1 surface expression during lymphocyte recirculation and relationship to lymphoid organ transit. J. Exp. Med. 201(2), 291-301 (2005).
34. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 427(6972), 355-360 (2004).
35. Allende ML, Dreier JL, Mandala S, Proia RL. Expression of the sphingosine 1-phosphate receptor, S1P1, on T-cells controls thymic emigration. J. Biol. Chem. 279(15), 15396-15401 (2004).
36. von Andrian UH, Mackay CR. T-cell function and migration. Two sides of the same coin. N. Engl. J. Med. 343(14), 1020-1034 (2000).
37. Schwab SR, Pereira JP, Matloubian M, Xu Y, Huang Y, Cyster JG. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 309(5741), 1735-1739 (2005).
38. Brinkmann V, Baumruker T. Pulmonary and vascular pharmacology of sphingosine 1-phosphate. Curr. Opin. Pharmacol. 6(3), 244-250 (2006).
39. Sanna MG, Wang SK, Gonzalez-Cabrera PJ et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chiral S1P1 antagonist in vivo. Nat. Chem. Biol. 2(8), 434-441 (2006).
40. Wei SH, Rosen H, Matheu MP et al. Sphingosine 1-phosphate type 1 receptor agonism inhibits transendothelial migration of medullary T cells to lymphatic sinuses. Nat. Immunol. 6(12), 1228-1235 (2005).
41. McVerry BJ, Garcia JG. Endothelial cell barrier regulation by sphingosine 1-phosphate. J. Cell. Biochem. 92(6), 1075-1085 (2004).
42. Rosen H, Sanna MG, Cahalan SM, Gonzalez-Cabrera PJ. Tipping the gatekeeper: S1P regulation of endothelial barrier function. Trends Immunol. 28(3), 102-107 (2007).
43. Tolle M, Levkau B, Keul P et al. Immunomodulator FTY720 Induces eNOS-dependent arterial vasodilatation via the lysophospholipid receptor S1P3. Circ. Res. 96(8), 913-920 (2005).
44. Coussin F, Scott RH, Wise A, Nixon GF. Comparison of sphingosine 1-phosphate-induced intracellular signaling pathways in vascular smooth muscles: differential role in vasoconstriction. Circ. Res. 91(2), 151-157 (2002).
45. Peters SL, Alewijnse AE. Sphingosine-1-phosphate signaling in the cardiovascular system. Curr. Opin. Pharmacol. 7(2), 186-192 (2007).
46. Chiba K, Hoshino Y, Suzuki C et al. FTY720, a novel immunosuppressant possessing unique mechanisms. I. Prolongation of skin allograft survival and synergistic effect in combination with cyclosporine in rats. Transplant Proc. 28(2), 1056-1059 (1996).
47. Hoshino Y, Suzuki C, Ohtsuki M, Masubuchi Y, Amano Y, Chiba K. FTY720, a novel immunosuppressant possessing unique mechanisms. II. Long-term graft survival induction in rat heterotopic cardiac allografts and synergistic effect in combination with cyclosporine A. Transplant Proc. 28(2), 1060-1061 (1996).
48. Chiba K, Yanagawa Y, Masubuchi Y et al. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. I. FTY720 selectively decreases the number of circulating mature lymphocytes by acceleration of lymphocyte homing. J. Immunol. 160(10), 5037-5044 (1998). •• First description of the immunomodulatory effects of FTY720.
49. Yanagawa Y, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats, III. Increase in frequency of CD62L-positive T cells in Peyer's patches by FTY720-induced lymphocyte homing. Immunology. 95(4), 591-594 (1998).
50. Chiba K, Yanagawa Y, Kataoka H, Kawaguchi T, Ohtsuki M, Hoshino Y. FTY720, a novel immunosuppressant, induces sequestration of circulating lymphocytes by acceleration of lymphocyte homing. Transplant Proc. 31(1-2), 1230-1233 (1999).
51. +T cells. J. Immunol. 170(7), 3662-3670 (2003).
52. Del Rio ML, Pabst O, Ramirez P, Penuelas-Rivas G, Forster R, Rodriguez-Barbosa JI. The thymus is required for the ability of FTY720 to prolong skin allograft survival across different histocompatibility MHC barriers. Transpl. Int. 20(10), 895-903 (2007).
53. Graler MH, Goetzl EJ. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G-protein-coupled receptors. FASEB J. 18(3), 551-553 (2004).
54. Liu CH, Thangada S, Lee MJ, Van Brocklyn JR, Spiegel S, Hla T. Ligand-induced trafficking of the sphingosine-1-phosphate receptor EDG-1. Mol. Biol. Cell. 10(4), 1179-1190 (1999).
55. Singer, II, Tian M, Wickham LA et al. Sphingosine-1-phosphate agonists increase macrophage homing, lymphocyte contacts, and endothelial junctional complex formation in murine lymph nodes. J. Immunol. 175(11), 7151-7161 (2005).
56. Baumruker T, Billich A, Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin. Investig. Drugs 16(3), 283-289 (2007).
57. Yanagawa Y, Sugahara K, Kataoka H, Kawaguchi T, Masubuchi Y, Chiba K. FTY720, a novel immunosuppressant, induces sequestration of circulating mature lymphocytes by acceleration of lymphocyte homing in rats. II. FTY720 prolongs skin allograft survival by decreasing T cell infiltration into grafts but not cytokine production in vivo. J. Immunol. 160(11), 5493-5499 (1998).
58. Maki T, Gottschalk R, Monaco AP. Prevention of autoimmune diabetes by FTY720 in nonobese diabetic mice. Transplantatio 74(12), 1684-1686 (2002).
59. Hwang MW, Matsumori A, Furukawa Y et al. FTY720, a new immunosuppressant, promotes long-term graft survival and inhibits the progression of graft coronary artery disease in a murine model of cardiac transplantation. Circulation 100(12), 1322-1329 (1999).
60. Kurose S, Ikeda E, Tokiwa M, Hikita N, Mochizuki M. Effects of FTY720, a novel immunosuppressant, on experimental autoimmune uveoretinitis in rats. Exp. Eye Res. 70(1), 7-15 (2000).
61. Fujino M, Funeshima N, Kitazawa Y et al. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 305(1), 70-77 (2003).
62. Kataoka H, Sugahara K, Shimano K et al. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2(6), 439-448 (2005).
63. Pinschewer DD, Ochsenbein AF, Odermatt B, Brinkmann V, Hengartner H, Zinkernagel RM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J. Immunol. 164(11), 5761-5770 (2000).
64. Brinkmann V, Pinschewer D, Chiba K, Feng L. FTY720: a novel transplantation drug that modulates lymphocyte traffic rather than activation. Trends Pharmacol. Sci. 21(2), 49-52 (2000).
65. Chiba K. FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors. Pharmacol. Ther. 108(3), 308-319 (2005).
66. Payne SG, Oskeritzian CA, Griffiths R et al. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 109(3), 1077-1085 (2007).
67. Kalyvas A, David S. Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 41(3), 323-335 (2004).
68. Sanchez T, Estrada-Hernandez T, Paik JH et al. Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. J. Biol. Chem. 278(47), 47281-47290 (2003).
69. Peng X, Hassoun PM, Sammani S et al. Protective effects of sphingosine 1-phosphate in murine endotoxin-induced inflammatory lung injury. Am. J. Respir. Crit. Care Med. 169(11), 1245-1251 (2004).
70. Czeloth N, Bernhardt G, Hofmann F, Genth H, Forster R. Sphingosine-1-phosphate mediates migration of mature dendritic cells. J. Immunol. 175(5), 2960-2967 (2005).
71. Lan YY, De Creus A, Colvin BL et al. The sphingosine-1-phosphate receptor agonist FTY720 modulates dendritic cell trafficking in vivo. Am. J. Transplant. 5(11), 2649-2659 (2005).
72. Muller H, Hofer S, Kaneider N et al. The immunomodulator FTY720 interferes with effector functions of human monocyte-derived dendritic cells. Eur. J. Immunol. 35(2), 533-545 (2005).
73. Dev KK, Mullershausen F, Mattes H et al. Brain sphingosine-1-phosphate receptors: implication for FTY720 in the treatment of multiple sclerosis. Pharmacol. Ther. 117(1), 77-93 (2008).
74. Pebay A, Toutant M, Premont J et al. Sphingosine-1-phosphate induces proliferation of astrocytes: regulation by intracellular signalling cascades. Eur. J. Neurosci. 13(12), 2067-2076 (2001).
75. Chae SS, Proia RL, Hla T. Constitutive expression of the S1P1 receptor in adult tissues. Prostaglandins Other Lipid Mediat. 73(1-2), 141-150 (2004).
76. Mullershausen F, Craveiro LM, Shin Y et al. Phosphorylated FTY720 promotes astrocyte migration through sphingosine-1-phosphate receptors. J. Neurochem. 102(4), 1151-1161 (2007).
77. Jaillard C, Harrison S, Stankoff B et al. Edg8/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival. J. Neurosci. 25(6), 1459-1469 (2005).
78. Miron VE, Jung CG, Kim HJ, Kennedy TE, Soliven B, Antel JP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann. Neurol. 63(1), 61-71 (2008). • First experimental study evaluating the effects of FTY720 on process extension, differentiation and survival of human oligodendrocyte progenitor cells.
79. Saini HS, Coelho RP, Goparaju SK et al. Novel role of sphingosine kinase 1 as a mediator of neurotrophin-3 action in oligodendrocyte progenitors. J. Neurochem. 95(5), 1298-1310 (2005).
80. Novgorodov AS, El-Alwani M, Bielawski J, Obeid LM, Gudz TI. Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration. FASEB J. 21(7), 1503-1514 (2007).
81. Yamagata K, Tagami M, Torii Y et al. Sphingosine 1-phosphate induces the production of glial cell line-derived neurotrophic factor and cellular proliferation in astrocytes. Glia 41(2), 199-206 (2003).
82. Sorensen SD, Nicole O, Peavy RD et al. Common signaling pathways link activation of murine PAR-1, LPA, and S1P receptors to proliferation of astrocytes. Mol. Pharmacol. 64(5), 1199-1209 (2003).
83. Rouach N, Pebay A, Meme W et al. S1P inhibits gap junctions in astrocytes: involvement of G and Rho GTPase/ROCK. Eur. J. Neurosci. 23(6), 1453-1464 (2006).
84. Sato K, Tomura H, Igarashi Y, Ui M, Okajima F. Exogenous sphingosine 1-phosphate induces neurite retraction possibly through a cell surface receptor in PC12 cells. Biochem. Biophys. Res. Commun. 240(2), 329-334 (1997).
85. MacLennan AJ, Devlin BK, Marks L, Gaskin AA, Neitzel KL, Lee N. Antisense studies in PC12 cells suggest a role for H218, a sphingosine 1-phosphate receptor, in growth-factor-induced cell-cell interaction and neurite outgrowth. Dev. Neurosci. 22(4), 283-295 (2000).
86. Toman RE, Payne SG, Watterson KR et al. Differential transactivation of sphingosine-1-phosphate receptors modulates NGFinduced neurite extension. J. Cell Biol. 166(3), 381-392 (2004).
87. Kimura A, Ohmori T, Ohkawa R et al. Essential roles of sphingosine 1-phosphate/S1P1 receptor axis in the migration of neural stem cells toward a site of spinal cord injury. Stem Cells 25(1), 115-124 (2007).
88. Harada J, Foley M, Moskowitz MA, Waeber C. Sphingosine-1-phosphate induces proliferation and morphological changes of neural progenitor cells. J. Neurochem. 88(4), 1026-1039 (2004).
89. Lucchinetti C, Brück W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47(6), 707-717 (2000).
90. Brück W, Kuhlmann T, Stadelmann C. Remyelination in multiple sclerosis. J. Neurol. Sci. 206(2), 181-185 (2003).
91. Franklin RJ. Why does remyelination fail in multiple sclerosis? Nat. Rev. Neurosci. 3(9), 705-714 (2002).
92. Dubois-Dalcq M, Ffrench-Constant C, Franklin RJ. Enhancing central nervous system remyelination in multiple sclerosis. Neuron 48(1), 9-12 (2005).
93. Coelho RP, Payne SG, Bittman R, Spiegel S, Sato-Bigbee C. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J. Pharmacol. Exp. Ther. 323(2), 626-635 (2007).
94. Jung CG, Kim HJ, Miron VE et al. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia 55(16), 1656-1667 (2007).
95. Balatoni B, Storch MK, Swoboda EM et al. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res. Bull. 74(5), 307-316 (2007).
96. Sofroniew MV. Reactive astrocytes in neural repair and protection. Neuroscientist 11(5), 400-407 (2005).
97. Budde K, Schmouder RL, Brunkhorst R et al. First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J. Am. Soc. Nephrol. 13(4), 1073-1083 (2002).
98. Budde K, Schmouder RL, Nashan B et al. Pharmacodynamics of single doses of the novel immunosuppressant FTY720 in stable renal transplant patients. Am. J. Transplant. 3(7), 846-854 (2003). •• First Phase I study on pharmacokinetics and pharmacodynamics of FTY720 in renal transplant patients.
99. Kovarik JM, Schmouder R, Barilla D, Wang Y, Kraus G. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br. J. Clin. Pharmacol. 57(5), 586-591 (2004). •• First study on FTY720 pharmacokinetic-pharmacodynamic relationship in healthy subjects.
100. Kahan BD, Karlix JL, Ferguson RM et al. Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, Phase I study. Transplantation 76(7), 1079-1084 (2003).
101. Skerjanec A, Tedesco H, Neumayer HH et al. FTY720, a novel immunomodulator in de novo kidney transplant patients: pharmacokinetics and exposure-response relationship. J. Clin. Pharmacol. 45(11), 1268-1278 (2005).
102. Kovarik JM, Schmouder R, Barilla D, Riviere GJ, Wang Y, Hunt T. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects. J. Clin. Pharmacol. 44(5), 532-537 (2004).
103. Hofmann M, Brinkmann V, Zerwes HG. FTY720 preferentially depletes naive T cells from peripheral and lymphoid organs. Int. Immunopharmacol. 6(13-14), 1902-1910 (2006).
104. Berard M, Tough DF. Qualitative differences between naive and memory T cells. Immunology 106(2), 127-138 (2002).
105. + T-lymphocyte subpopulations expressing chemokine and adhesion receptors. Nephrol. Dial. Transplant. 19(3), 702-713 (2004).
106. Schuurman HJ, Menninger K, Audet M et al. Oral efficacy of the new immunomodulator FTY720 in cynomolgus monkey kidney allotransplantation, given alone or in combination with cyclosporine or RAD. Transplantation. 74(7), 951-960 (2002).
107. Brinkmann V, Cyster JG, Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4(7), 1019-1025 (2004).
108. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291(5512), 2413-2417 (2001).
109. Clemens JJ, Davis MD, Lynch KR, Macdonald TL. Synthesis of para-alkyl aryl amide analogues of sphingosine-1-phosphate: discovery of potent S1P receptor agonists. Bioorg. Med. Chem. Lett. 13(20), 3401-3404 (2003).
110. Fujita T, Hirose R, Yoneta M et al. Potent immunosuppressants, 2-alkyl-2-aminopropane-1,3-diols. J. Med. Chem. 39(22), 4451-4459 (1996).
111. Parrill AL, Wang D, Bautista DL et al. Identification of Edg1 receptor residues that recognize sphingosine 1-phosphate. J. Biol. Chem. 275(50), 39379-39384 (2000).
112. Kiuchi M, Adachi K, Kohara T et al. Synthesis and immunosuppressive activity of 2-substituted 2-aminopropane-1,3-diols and 2-aminoethanols. J. Med. Chem. 43(15), 2946-2961 (2000).
113. Kovarik JM, Hartmann S, Bartlett M et al. Oral-intravenous crossover study of fingolimod pharmacokinetics, lymphocyte responses and cardiac effects. Biopharm. Drug Dispos. 28(2), 97-104 (2007).
114. Kovarik JM, Schmouder RL, Slade AJ. Overview of FTY720 clinical pharmacokinetics and pharmacology. Ther. Drug. Monit. 26(6), 585-587 (2004).
115. Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554(1-2), 189-193 (2003).
116. Kharel Y, Lee S, Snyder AH et al. Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720. J. Biol. Chem. 280(44), 36865-36872 (2005).
117. Zemann B, Kinzel B, Muller M et al. Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720. Blood 107(4), 1454-1458 (2006). • Proof that SphK2 is the main enzyme for FTY720 phosphorylation in vivo.
118. Park SI, Felipe CR, Machado PG et al. Pharmacokinetic/ pharmacodynamic relationships of FTY720 in kidney transplant recipients. Braz. J. Med. Biol. Res. 38(5), 683-694 (2005).
119. Kovarik JM, Schmouder RL, Serra D et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J. Clin. Pharmacol. 45(4), 446-452 (2005).
120. Kovarik JM, Schmouder RL, Hartmann S et al. Fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function. J. Clin. Pharmacol. 46(2), 149-156 (2006). •• First study showing a direct relationship between FTY720 blood levels and hepatic function impairment.
121. Meno-Tetang GM, Li H, Mis S et al. Physiologically based pharmacokinetic modeling of FTY720 (2-amino-2[2-(-4-octylphenyl)ethyl]propane-1, 3-diol hydrochloride) in rats after oral and intravenous doses. Drug Metab. Dispos. 34(9), 1480-1487 (2006).
122. Foster CA, Howard LM, Schweitzer A et al. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the CNS during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J. Pharmacol. Exp. Ther. 323(2), 469-475 (2007). •• First study demonstrating the preferential distribution of FTY720 in the CNS white matter.
123. Billich A, Bornancin F, Devay P, Mechtcheriakova D, Urtz N, Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278(48), 47408-47415 (2003).
124. Zimmerlin AG, Patten CJ. Role of CYP4F in the metabolic clearance of FTY720: prediction of low drug to drug interaction potential [abstract]. Transplantation 69(Suppl.), S191 (2000).
125. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 360(9340), 1155-1162 (2002).
126. Kahan BD. Update on pharmacokinetic/pharmacodynamic studies with FTY720 and sirolimus. Ther. Drug Monit. 24(1), 47-52 (2002).
127. Kovarik JM, Hsu CH, Skerjanec A, Riviere GJ, Schmouder R. FTY720 disposition is not affected by demographic or clinical factors in de novo kidney transplant patients. Am. J. Transplant. 5(Suppl. 3), 332 (2003).
128. Kovarik JM, Slade A, Voss B et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int. J. Clin. Pharmacol. Ther. 45(2), 98-109 (2007).
129. Chiba K, Matsuyuki H, Maeda Y, Sugahara K. Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell. Mol. Immunol. 3(1), 11-19 (2006).
130. Rausch M, Hiestand P, Foster CA, Baumann DR, Cannet C, Rudin M. Predictability of FTY720 efficacy in experimental autoimmune encephalomyelitis by in vivo macrophage tracking: clinical implications for ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging. J. Magn. Reson. Imaging. 20(1), 16-24 (2004).
131. Webb M, Tham CS, Lin FF et al. Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J. Neuroimmunol. 153(1-2), 108-121 (2004).
132. Schubart A, Seabrook T, Rausch M et al. CNS mediated effects of FTY720 (fingolimod) in EAE. Neurology 60(Suppl. 1), A315 (2007).
133. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) in relapsing multiple sclerosis: 24-month results of the Phase II study. Multiple Sclerosis 12(1 Suppl.), S101 (2006).
134. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 352(9139), 1498-1504 (1998).
135. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39(3), 285-294 (1996).
136. The IFNB Multiple Sclerosis Study Group. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43(4), 655-661 (1993).
137. Paty DW, Li DK. Interferon β-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 43(4), 662-667 (1993).
138. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45(7), 1268-1276 (1995).
139. Hartung HP, Gonsette R, Konig N et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360(9350), 2018-2025 (2002).
140. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 354(9), 899-810 (2006).
141. Stott VL, Hurrell MA, Anderson TJ. Reversible posterior leukoencephalopathy syndrome: a misnomer reviewed. Intern. Med. J. 35(2), 83-90 (2005).
142. Oppenheimer F, Mulgaonkar S, Ferguson R et al. Impact of long-term therapy with FTY720 or mycophenolate mofetil on cardiac conduction and rhythm in stable adult renal transplant patients. Transplantation 83(5), 645-648 (2007).
143. Schmouder R, Serra D, Wang Y et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J. Clin. Pharmacol. 46(8), 895-904 (2006).
144. Mulgaonkar S, Tedesco H, Oppenheimer F et al. FTY720/cyclosporine regimens in de novo renal transplantation: a 1-year dose-finding study. Am. J. Transplant. 6(8), 1848-1857 (2006).
145. Sanna MG, Liao J, Jo E et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem. 279(14), 13839-13848 (2004). • Demonstration that FTY720-induced bradycadia depends on S1P3 signaling.
146. Koyrakh L, Roman MI, Brinkmann V, Wickman K. The heart rate decrease caused by acute FTY720 administration is mediated by the G protein-gated potassium channel I. Am. J. Transplant. 5(3), 529-536 (2005). • Demonstration that FTY720 induced-bradycardia is mediated by IKACh activation.
147. Tedesco-Silva H, Mourad G, Kahan BD et al. FTY720, a novel immunomodulator: efficacy and safety results from the first phase 2A study in de novo renal transplantation. Transplantation 79(11), 1553-1560 (2005).
148. Roviezzo F, Di Lorenzo A, Bucci M et al. Sphingosine-1-phosphate/ sphingosine kinase pathway is involved in mouse airway hyperresponsiveness. Am. J. Respir. Cell Mol. Biol. 36(6), 757-762 (2007).
149. Pfaff M, Powaga N, Akinci S et al. Activation of the SPHK/S1P signalling pathway is coupled to muscarinic receptor-dependent regulation of peripheral airways. Respir. Res. 6, 48 (2005).
150. Massberg S, von Andrian UH. Fingolimod and sphingosine-1-phosphate - modifiers of lymphocyte migration. N. Engl. J. Med. 355(11), 1088-1091 (2006).